Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Oncology

• Publication date

  2002-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2002.03.052PMID 12202672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Managing Cancer-Related Anorexia/Cachexia

  2012cited by this paper
• Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.

  2002cited by this paper
• Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.

  2002cited by this paper
• Modern management of the cancer anorexia-cachexia syndrome

  2001cited by this paper
• The Effects of Propofol in the Area Postrema of Rats

  2001cited by this paper
• Paroxetine for the prevention of depression induced by high-dose interferon alfa.

  2001cited by this paper
• Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI.

  2001cited by this paper
• [Acute pancreatitis after high-dose interferon therapy in a patient with melanoma].

  2001cited by this paper
• [Acute pancreatitis after high-dose interferon therapy in a patient with melanoma].

  2001cited by this paper
• Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review.

  2001cited by this paper
• High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

  2001cited by this paper
• High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

  2001cited by this paper
• Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

  2001cited by this paper
• Interaction of prefrontal cortical and hypothalamic systems in the pathogenesis of depression.

  2000cited by this paper
• Acute pancreatitis attributed to the use of interferon alfa-2b.

  2000cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Prophylactic treatment of depression induced by interferon-alpha.

  2000cited by this paper
• Interferons, serotonin and neurotoxicity

  2000cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000cited by this paper
• Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.

  2000cited by this paper
• Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology.

  2000cited by this paper
• Prophylactic Treatment of Depression Induced by Interferon-α

  2000cited by this paper
• Cutaneous reactions associated with alpha interferon therapy.

  2000cited by this paper
• Modern management of the cancer anorexia—cachexia syndrome

  2000cited by this paper
• Sertraline treatment of interferon‐alfa‐induced depressive disorder

  2000cited by this paper
• Adjuvant therapy of melanoma with interferon‐alpha‐2b is associated with mania and bipolar syndromes

  2000cited by this paper
• Cytokines and depression: fortuitous or causative association?

  1999cited by this paper
• Cancer-related fatigue: guidelines for evaluation and management.

  1999cited by this paper
• [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].

  1999cited by this paper
• The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences.

  1999cited by this paper
• Mood and cognitive disorders in cancer patients receiving cytokine therapy.

  1999cited by this paper
• Treatment of depression with antiglucocorticoid drugs.

  1999cited by this paper
• Regulation of the hypothalamo-pituitary-adrenal axis by cytokines.

  1999cited by this paper
• Rural surgery, caring for developing communities.

  1999cited by this paper
• Neurotoxicity of interferon‐α in melanoma therapy

  1998cited by this paper
• A perspective on the clinical effectiveness and tolerance of interferon-alpha.

  1998cited by this paper
• Cytokines and anorexia: a brief overview.

  1998cited by this paper
• Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial.

  1998cited by this paper
• Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders.

  1998cited by this paper
• Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes.

  1998cited by this paper
• The effects of interferon-alpha on the production and action of other cytokines.

  1998cited by this paper
• Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.

  1998cited by this paper
• Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha.

  1998cited by this paper
• Mood and cognitive side effects of interferon-α therapy

  1998cited by this paper
• Fatigue: definitions, mechanisms, and paradigms for study.

  1998cited by this paper
• Cytokines in the neuroendocrine system.

  1998cited by this paper
• Pharmacokinetics and Biotransformation of Mirtazapine in Human Volunteers

  1998cited by this paper
• Mood and cognitive side effects of interferon-alpha therapy.

  1998cited by this paper
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases

  1998cited by this paper
• Adjuvant IFNα2 therapy of melanoma

  1998cited by this paper
• The effects of interferon-alpha on the production and action of other cytokines.

  1998cited by this paper
• Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.

  1998cited by this paper
• Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

  1998cited by this paper
• Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

  1998cited by this paper
• Cancer-related fatigue: clinical practice issues.

  1998cited by this paper
• Fatigue in patients with cancer.

  1998cited by this paper
• Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.

  1998cited by this paper
• Mania induced by withdrawal of treatment with interferon alfa.

  1998cited by this paper
• Adjuvant IFN alpha2 therapy of melanoma.

  1998cited by this paper
• Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α

  1998cited by this paper
• Methylphenidate therapy improves cognition, mood, and function of brain tumor patients.

  1998cited by this paper
• Neuroendocrine and immune system interactions in stress and depression.

  1998cited by this paper
• Manic episodes in two patients treated with interferon alpha.

  1997cited by this paper
• Acute phase proteins in major depression.

  1997cited by this paper
• Mirtazapine: An Antidepressant with Noradrenergic and Specific Serotonergic Effects

  1997cited by this paper
• Hypertriglyceridemia During Long-Term Interferon-α Therapy in a Series of Hematologic Patients

  1997cited by this paper
• The clinical relevance of preclinical data: mirtazapine, a model compound.

  1997cited by this paper
• Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma.

  1997cited by this paper
• The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans.

  1996cited by this paper
• Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids.

  1996cited by this paper
• Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes.

  1996cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukemia.

  1996cited by this paper
• Treatment of neurotoxic side effects of interferon-alpha with naltrexone.

  1995cited by this paper
• Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

  1995cited by this paper
• Treatment of Neurotoxic Side Effects of Interferon-α with Naltrexone

  1995cited by this paper
• Regulation of the HPA axis by cytokines.

  1995cited by this paper
• Evaluation of efficacy of adjuvant rIFN-alfa-2a in melanoma patients with regional nodal metastases (abstract)

  1995cited by this paper
• Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration.

  1995cited by this paper
• Interleukin‐6 Serum Levels in Depressed Patients before and after Treatment with Fluoxetine

  1995cited by this paper
• Successful treatment of interferon-alpha-induced mood disorder with nortriptyline.

  1995cited by this paper
• Hypertriglyceridemia may be severe in CML patients treated with interferon‐α

  1995cited by this paper
• Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes.

  1995cited by this paper
• More on interferon-induced cutaneous necrosis.

  1995cited by this paper
• Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.

  1995cited by this paper
• Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment.

  1995cited by this paper
• Safety of mirtazapine: a review

  1995cited by this paper
• The area postrema and vomiting.

  1994cited by this paper
• Estrogenic Effects on Memory in Women a

  1994cited by this paper
• Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

  1994cited by this paper
• Interferon-α, 5-FU and prednisone in metastatic renal cell carcinoma: A phase II study

  1994cited by this paper
• Cognitive Pattern in Men and Women Is Influenced by Fluctuations in Sex Hormones

  1994cited by this paper
• Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression.

  1993cited by this paper
• Fluoxetine treatment of depression caused by interferon-alpha.

  1993cited by this paper
• Cytokines and hypothalamic-pituitary function.

  1993cited by this paper
• Group psychotherapy during radiotherapy: effects on emotional and physical distress.

  1993cited by this paper
• Fluoxetine treatment of depression caused by interferon-alpha.

  1993cited by this paper
• Psoriasis exacerbation induced by interferon-alpha. Report of two cases.

  1993cited by this paper
• Severe hypertriglyceridaemia and interferon-alpha.

  1993cited by this paper

• Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models.

  2026cites this paper
• Efficacy and safety of aerosol inhalation of recombinant human interferon-α2b injection in children hospitalized with human adenovirus pneumonia: a prospective, multicenter, randomized, controlled trial in China.

  2026cites this paper
• ISG15 mRNA transcript level in circulating leucocytes prognostic of overall survival in hepatocellular carcinoma patients and correlated with quality of life disturbances involved in anorexia-cachexia

  2025cites this paper
• Hyaluronic Acid-Coated Silica Nanoparticles for Targeted Delivery of Nitric Oxide to Cancer Cells.

  2024cites this paper
• Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma.

  2024cites this paper
• Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

  2024cites this paper
• Impact of Adjuvant Interferon Therapy on Survival Outcomes for Cutaneous Melanoma With Parotid Involvement

  2024cites this paper
• Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro

  2023cites this paper
• Gene-based delivery of immune-activating cytokines for cancer treatment.

  2023cites this paper
• From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics

  2023cites this paper
• Recent and future perspectives on engineering interferons and other cytokines as therapeutics.

  2022cites this paper
• A Systematic Review on Interferon Alpha-Induced Cognitive Impairment in Hepatitis C Patients.

  2022cites this paper
• Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models

  2022cites this paper
• Adverse Renal Effects of Anticancer Immunotherapy: A Review

  2022cites this paper
• Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle

  2022cites this paper
• Type I Interferons Enhance the Repair of Ultraviolet Radiation-Induced DNA Damage and Regulate Cutaneous Immune Suppression

  2022influential citation
• Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study

  2022cites this paper
• Interferon-α1b for the treatment of metastatic melanoma: results of a retrospective study

  2021cites this paper
• Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities

  2021cites this paper
• Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy

  2021cites this paper
• Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2

  2021cites this paper
• The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms

  2021cites this paper
• Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms

  2021cites this paper
• Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas

  2021cites this paper
• Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

  2021cites this paper
• Age-related differences of immune infiltrates in pheochromocytomas and paragangliomas

  2020cites this paper
• Gastrointestinal Toxicities of Immunotherapy

  2020cites this paper
• Interferons: role in cancer therapy.

  2020cites this paper
• Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.

  2020cites this paper
• Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.

  2019cites this paper
• Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

  2019cites this paper
• Oncology and Hematology Medications

  2019cites this paper
• Asthenia

  2019cites this paper
• CJON BOOK EXCERPT SERIES

  2019cites this paper
• A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

  2019cites this paper
• The Stimulation of Dendritic Cells by Cationic Lipids

  2019cites this paper
• Interferon Lambda: Toward a Dual Role in Cancer

  2019cites this paper
• A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

  2018cites this paper
• Biological alterations in renal and hepatic tissues by a novel gold (III) anti-cancerous compound

  2018cites this paper
• Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.

  2018cites this paper
• A synthetic dendritic cell platform for immune activation

  2018cites this paper
• Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer

  2018cites this paper
• Chapter 20 Therapeutic Agents for Advanced Melanoma

  2017cites this paper
• Update on adjuvant melanoma therapy

  2017cites this paper
• Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

  2017cites this paper
• An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.

  2017cites this paper
• Mental health services use by melanoma patients receiving adjuvant interferon: association of pre-treatment mental health care with early discontinuation.

  2017cites this paper
• Recognizing and managing on toxicities in cancer immunotherapy

  2017cites this paper
• Melanoma Incidence and Mortality in the Elderly

  2017cites this paper
• Dose-Escalation Study Evaluating Pegylated Interferon Alpha-2 a in Patients with Cutaneous T-Cell Lymphoma Running head : Pegylated IFN alpha-2 a in cutaneous T-cell lymphoma Names of authors :

  2017cites this paper
• Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study

  2017cites this paper
• Adverse Events in Cancer Immunotherapy.

  2017cites this paper
• Dose‐escalation study evaluating pegylated interferon alpha‐2a in patients with cutaneous T‐cell lymphoma

  2017cites this paper
• Cuban interferon alpha-2 b . Thirty years as an effective and safe drug

  2017cites this paper
• Tolerability, pharmacokinetics and antiviral activity of rHSA/IFN&agr;2a for the treatment of chronic hepatitis B infection

  2017cites this paper
• The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma

  2017influential citation
• Retraction notice

  2017cites this paper
• IFN-lambda therapy: current status and future perspectives.

  2016cites this paper
• The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review

  2016cites this paper
• [Updates on prevention and treatment of melanoma: Pharmacist involvements and challenges].

  2016cites this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2016cites this paper
• Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation

  2016cites this paper
• IFN-λ cancer immunotherapy: new kid on the block.

  2016cites this paper
• A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type I IFN Response

  2015cites this paper
• Frβ-directed car T cells for immunotherapy of cancer

  2015cites this paper
• Interferon-α Induces Neurotoxicity Through Activation of the Type I Receptor and the GluN2A Subunit of the NMDA Receptor

  2015cites this paper
• POJAVNOST UMORA KAO SIMPTOMA U ZLOĆUDNIH BOLESTI

  2015cites this paper
• Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.

  2015cites this paper
• Interferon-α2b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels.

  2015cites this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2015cites this paper
• Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience

  2015cites this paper
• Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice

  2015cites this paper
• PAMPering immune responses : spotlight on helper cells for dendritic cell vaccination

  2015cites this paper
• Combination immunotherapy for high-risk resected and metastatic melanoma patients.

  2014cites this paper
• Hepatotoxicity Secondary to Chemotherapy

  2014cites this paper
• Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy

  2014influential citation
• Short-Term Intratumoral Interleukin-12 Expressed from an Alphaviral Vector Is Sufficient to Induce an Efficient Antitumoral Response Against Spontaneous Hepatocellular Carcinomas

  2014cites this paper
• Treatment of Cutaneous Melanoma

  2014cites this paper
• Mitigating the toxic effects of anticancer immunotherapy

  2014cites this paper
• Health-related Quality of Life, Fatigue, and Depression Under Low-Dose IFN-&agr; Therapy in Melanoma Patients

  2014cites this paper
• Therapeutic Spectrum of Bacterial Metabolites

  2014cites this paper
• Side Effects of Interferon Therapy in Adolescent Melanoma

  2014cites this paper
• Therapeutic Spectrum of Bacterial Metabolites

  2014cites this paper
• Targeting Interferon‐α to the Liver: Apolipoprotein A‐I as a Scaffold for Protein Delivery

  2013cites this paper
• Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy

  2013cites this paper
• Therapeutic Agents for Advanced Melanoma

  2013cites this paper
• Melanoma vaccines: trials and tribulations

  2013cites this paper
• Modulation of Inflammasome-Mediated Pulmonary Immune Activation by Type I IFNs Protects Bone Marrow Homeostasis during Systemic Responses to Pneumocystis Lung Infection

  2013cites this paper
• Adjuvant Treatment of Melanoma

  2013cites this paper
• Generalized lymphadenopathy mimicking malignant lymph node metastases after interferon-α2b therapy for melanoma.

  2013cites this paper
• Self‐efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression

  2013cites this paper
• Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

  2013cites this paper
• Type I interferons: ancient peptides with still under-discovered anti-cancer properties.

  2013influential citation
• Lung Infection Pneumocystis during Systemic Responses to IFNs Protects Bone Marrow Homeostasis Pulmonary Immune Activation by Type I Modulation of Inflammasome-Mediated

  2013cites this paper
• CYTOKINES AND INTERFERONS

  2013cites this paper
• Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms”

  2013cites this paper
• Adjuvant Treatment of Melanoma

  2013cites this paper
• Topical TLR 7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

  2012cites this paper
• Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

  2012cites this paper
• Interferon-α (IFNα) neurotoxicity.

  2012cites this paper